FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed, including TB-500, are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

The vascular system ages through a cascade of interconnected changes – endothelial dysfunction, arterial stiffening, impaired angiogenesis, chronic low-grade inflammation – that collectively degrade the body’s ability to perfuse tissues with oxygenated blood. While most aging research addresses these processes through systemic interventions, bioregulator peptides offer a fundamentally different approach: tissue-specific gene expression modulation targeting the vascular endothelium directly. Vesugen, a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), represents the vascular-targeted compound within the Khavinson bioregulator research framework.

Developed at the Saint Petersburg Institute of Bioregulation and Gerontology, Vesugen was synthesized based on active peptide sequences identified in vascular tissue extracts. Unlike larger signaling molecules that act through extracellular receptor binding, Vesugen’s ultra-short structure – just three amino acids at approximately 390 Da – positions it within a class of compounds hypothesized to penetrate cell and nuclear membranes and interact directly with DNA in gene promoter regions. This proposed mechanism makes Vesugen one of the more mechanistically specific compounds in the bioregulator literature, with published molecular docking data identifying a particular gene target: the MKI67 promoter region.

This article examines the published research on Vesugen’s molecular interactions, its documented effects on vascular endothelial cell proliferation and senescence markers, and its position within the broader bioregulator peptide research program – including its complementary relationship with the cardiac-targeted compound Cardiogen in cardiovascular aging research.

Key Takeaways

• Vesugen (Lys-Glu-Asp) is a synthetic tripeptide studied for its proposed ability to modulate gene expression in vascular endothelial cells through direct interaction with DNA in gene promoter regions.
• Molecular docking studies have identified Vesugen’s binding site within the minor groove of the MKI67 gene promoter, a proliferation marker – representing one of the most mechanistically specific findings in the bioregulator literature.
• Published research in animal models has documented increased microvasculature density (2.5–2.8-fold) and measurable changes in cerebral perfusion (~1.7-fold) in aged hypertensive rats treated with vascular peptide bioregulators.
• Vesugen has been studied for its effects on multiple vascular gene targets, including Ki-67 (proliferation), SIRT1 (longevity-associated signaling), connexins (cell-cell communication), and endothelin-1 (vasoactive signaling).
• As with other bioregulator peptides, the majority of Vesugen research originates from a single institutional network, and independent international replication remains a significant gap in the evidence base.

Vesugen Amino Acid Sequence and Molecular Properties

Vesugen is composed of three amino acids – lysine, glutamic acid, and aspartic acid – arranged in the sequence Lys-Glu-Asp (KED). With a molecular weight of approximately 390.39 Da and the molecular formula C₁₅H₂₆N₄O₈, it is among the smallest bioactive peptides studied in the aging research context (1).

The compound’s structural simplicity is central to its proposed mechanism. At fewer than 400 Da, Vesugen falls well below the conventional molecular weight thresholds for cell membrane permeability. The bioregulator hypothesis proposes that peptides of this size can bypass receptor-mediated endocytosis entirely, penetrating cell membranes, cytoplasm, and nuclear envelopes through passive or non-receptor-mediated transport to reach chromatin directly (2).

Structurally, Vesugen’s KED sequence differs from the AED motif shared by several other bioregulators – Cardiogen (AEDR), Cortagen (AEDP), and Ovagen (AEDL). While those compounds share an alanine-glutamic acid-aspartic acid core with tissue specificity attributed to the C-terminal residue, Vesugen replaces the N-terminal alanine with lysine. The lysine residue carries a positively charged amino group at physiological pH, which may alter the peptide’s electrostatic profile and its affinity for specific DNA sequences in vascular endothelial chromatin. This structural divergence from the AED family suggests that Vesugen’s vascular specificity may operate through a distinct binding mode, a proposition supported by the molecular docking data discussed below.

MKI67 Promoter Binding: A Mechanistically Specific Finding

Among the most notable findings in the Vesugen literature is the identification of a specific gene target through molecular docking analysis. Research by Khavinson, Tarnovskaya, Linkova, and colleagues demonstrated that Vesugen binds within the minor groove of the MKI67 gene promoter region, contacting the CATC sequence located approximately 14 base pairs from the transcription start site (3).

The MKI67 gene encodes Ki-67, a nuclear protein universally used as a marker of cellular proliferation. Ki-67 is expressed during all active phases of the cell cycle (G1, S, G2, and mitosis) but is absent in quiescent (G0) cells. In vascular endothelial cells, Ki-67 expression naturally declines with age as cells enter replicative senescence – the state in which cells remain metabolically active but lose their proliferative capacity. This decline in endothelial proliferative potential is a key contributor to impaired vascular repair and angiogenesis in aged tissues.

The molecular docking data showed that Vesugen’s interaction with the MKI67 promoter occurs through hydrogen bonding between the peptide and DNA base pairs in the minor groove. This binding is proposed to modulate transcription factor accessibility at the MKI67 promoter, facilitating increased Ki-67 expression and, consequently, measurable shifts in endothelial cell proliferative activity (3).

This finding is significant within the bioregulator field because it moves beyond the general claim that short peptides modulate gene expression and identifies a specific peptide-gene interaction with a defined binding site. While molecular docking is a computational prediction tool and binding predicted in silico does not guarantee the same interaction occurs in vivo with the same affinity and specificity, it provides a testable hypothesis that elevates the mechanistic specificity of Vesugen research above many other compounds in the bioregulator class.

Vesugen and Vascular Endothelial Cell Proliferation and Senescence

The Ki-67 pathway identified through molecular docking connects to a broader body of experimental evidence on Vesugen’s effects on vascular endothelial cell behavior. In cell culture studies, Vesugen was associated with increased Ki-67 protein synthesis in vascular endothelial cells derived from both young and aged animals, consistent with the proposed MKI67 promoter activation mechanism (3).

Beyond Ki-67, published research has documented the compound’s influence on multiple gene expression targets relevant to endothelial cell function and senescence. SIRT1 (sirtuin-1) expression was upregulated in KED-treated endothelial cells – a finding of particular interest given SIRT1’s established role as a regulator of cellular stress responses, DNA repair, and metabolic homeostasis. SIRT1 activity declines with age in vascular tissue, and increased SIRT1 expression has been associated with measurable changes in endothelial function parameters in multiple experimental models (4).

Conversely, p53 expression was downregulated in KED-treated endothelial cells. As discussed in the context of Cardiogen and cardiac tissue, p53 functions as both a tumor suppressor and a regulator of cellular senescence. In the vascular endothelium, elevated p53 activity drives cells toward growth arrest and apoptosis – protective against malignancy but detrimental to vascular repair capacity. The observed reduction in p53 expression is consistent with the compound’s observed proliferative effects and suggests a mechanism through which replicative senescence markers may be modulated in aged endothelial populations (3).

The combined gene expression profile – increased Ki-67 and SIRT1, decreased p53 – describes a shift from a senescent, growth-arrested endothelial phenotype toward a more proliferative, stress-resistant state. This multi-target modulation is consistent with the bioregulator hypothesis that short peptides influence chromatin accessibility broadly within a tissue type rather than acting on a single molecular target.

Vesugen in Microvasculature Density and Cerebral Perfusion Studies

Translating from cell culture to whole-tissue effects, published animal studies have investigated the impact of vascular peptide bioregulators on microvasculature density and tissue perfusion. In aged hypertensive rats, treatment with vascular peptide bioregulator increased microvasculature density in the pial membrane (the innermost meningeal layer covering the brain) by approximately 2.5 to 2.8-fold compared to untreated age-matched controls (5).

The same study documented measurable changes in cerebral tissue perfusion, with blood oxygen saturation in cortical microvasculature increasing approximately 1.7-fold in treated animals. These findings are particularly relevant to aging research because age-related cerebrovascular changes – reduced capillary density, impaired blood-brain barrier function, diminished cerebral perfusion – are increasingly recognized as contributors to cognitive decline and neurodegenerative processes (5).

These microvasculature findings connect mechanistically to the endothelial cell proliferation data from in vitro studies. If Vesugen modulates endothelial cell proliferative capacity through Ki-67 upregulation and senescence marker reduction, the downstream consequence in intact tissue would be increased angiogenic activity – the formation of new capillaries from existing vessels. The observed increase in microvasculature density is consistent with this proposed mechanism, though the causal chain from molecular docking prediction to cell culture proliferation to whole-tissue angiogenesis involves multiple inferential steps that warrant further investigation.

Vascular Adhesion, Inflammation, and Endothelial Signaling

Beyond proliferation and senescence, published research has investigated Vesugen’s effects on vascular inflammatory and adhesion pathways – processes central to atherosclerosis and age-related vascular disease.

Research on the KED peptide documented regulation of adhesion molecule expression and thrombogenic markers in both intact and damaged vascular endothelium. Specifically, Vesugen was associated with modulated expression of endothelin-1 (EDN1) in atherosclerotic and restenotic endothelial models. Endothelin-1 is one of the most potent vasoconstrictors produced by endothelial cells, and its overexpression is a hallmark of endothelial dysfunction in aged and diseased vasculature (4).

Connexin expression, particularly GJA1 (Connexin-43), was also modulated in KED-treated endothelial cells, with expression levels shifting toward patterns observed in younger tissue. Connexins form gap junctions between adjacent endothelial cells, enabling direct cell-to-cell communication that coordinates vascular tone, permeability, and inflammatory responses. Age-related changes in connexin expression disrupt this intercellular signaling network, contributing to endothelial barrier dysfunction and dysregulated vascular reactivity (4).

Additionally, the KED tripeptide reduced E-selectin expression in atherosclerotic endothelial models and decreased cell adhesion between monocytes and activated endothelial cells – a key early step in atherosclerotic plaque formation. These inflammation-modulating and adhesion-related effects complement the compound’s observed proliferative actions, suggesting a multi-pathway influence on vascular endothelial signaling that extends beyond growth regulation to include modulation of the inflammatory and adhesive processes studied in vascular aging research (6).

Vesugen and Cardiogen: Complementary Cardiovascular Bioregulators

Within the Khavinson bioregulator framework, Vesugen and Cardiogen represent complementary approaches to cardiovascular aging – one targeting the vasculature, the other targeting the myocardium. This distinction reflects a core principle of the bioregulator hypothesis: that different tissue types within the same organ system require distinct peptide sequences for optimal gene expression modulation.

The cardiovascular system’s dependence on both components makes their complementary study particularly informative. Cardiac function requires not only healthy myocardium (contractile cells capable of generating force) but also a functional vascular network (endothelial-lined vessels capable of delivering oxygen and nutrients). Age-related decline in either component compromises the entire system: myocardial dysfunction reduces cardiac output regardless of vascular health, while vascular deterioration starves even healthy myocardium of adequate perfusion.

The published gene expression data support this complementary relationship. Cardiogen modulates genes involved in contractile protein synthesis, calcium handling, and cardiomyocyte proliferation, while Vesugen targets endothelial proliferation (Ki-67), vascular signaling (endothelin-1, connexins), and longevity-associated pathways (SIRT1). Both compounds downregulate p53 in their respective tissue types, suggesting a shared senescence-modulating mechanism operating through tissue-specific chromatin landscapes (2).

The geroprotective framework established in Khavinson’s two-part review series – with preclinical evidence in Communication 1 (7) and clinical observations in Communication 2 (8) – provides the broader theoretical context for this complementary approach. Researchers investigating cardiovascular aging through the bioregulator lens can explore both the Vesugen and Cardiogen compounds, alongside the pineal bioregulator Epithalon for systemic longevity research.

Vesugen Evidence Limitations and Research Directions

Researchers evaluating Vesugen should consider the same institutional concentration caveat that applies across the bioregulator class. The majority of published Vesugen research originates from the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated institutions. While the quality of individual studies is often methodologically sound – particularly the molecular docking work on the MKI67 promoter – the absence of independent international replication limits the strength of conclusions that can be drawn.

The molecular docking finding, while mechanistically specific, represents a computational prediction. In silico binding does not confirm in vivo interaction at the same site with the same affinity, particularly given the crowded molecular environment of the nucleus where competing DNA-binding proteins and chromatin remodeling complexes are present. Experimental validation using techniques such as chromatin immunoprecipitation (ChIP) or electrophoretic mobility shift assays (EMSA) with Vesugen and the MKI67 promoter would substantially strengthen the mechanistic case.

The animal model data on microvasculature density and cerebral perfusion, while striking in magnitude (2.5–2.8-fold increases), derive from studies with limited sample sizes and require replication under blinded, controlled conditions with pre-registered protocols. The pharmacokinetic profile of Vesugen – including its absorption, distribution to vascular endothelium, nuclear penetration efficiency, and metabolic clearance – remains incompletely characterized.

For researchers exploring vascular aging pathways, Vesugen represents a compound with an unusually specific proposed mechanism (MKI67 promoter binding) supported by convergent in vitro, molecular docking, and animal model data. These attributes make it a productive target for further investigation, particularly for research groups with the capacity to independently validate the published mechanistic findings. The Pure Health Peptides catalog offers Vesugen and related bioregulator compounds for qualified research investigators.

Frequently Asked Questions

1. What is Vesugen, and how does it differ structurally from other bioregulator peptides?

Vesugen is a synthetic tripeptide composed of the amino acid sequence Lys-Glu-Asp (KED), with a molecular weight of approximately 390 Da. Unlike several other bioregulators that share the Ala-Glu-Asp (AED) motif – such as Cardiogen (AEDR), Cortagen (AEDP), and Ovagen (AEDL) – Vesugen features lysine at its N-terminus instead of alanine. The lysine residue carries a positively charged amino group at physiological pH, which may alter the peptide’s electrostatic interaction profile with DNA and contribute to its proposed vascular tissue specificity.

2. What is the significance of Vesugen’s interaction with the MKI67 gene promoter?

Molecular docking studies identified Vesugen’s binding site within the minor groove of the MKI67 gene promoter, approximately 14 base pairs from the transcription start site (3). The MKI67 gene encodes Ki-67, a universal marker of cellular proliferation that is absent in quiescent cells. This finding is significant because it identifies a specific peptide-gene interaction rather than documenting general tissue-level effects, providing a testable mechanistic hypothesis. In vascular endothelial cells, Ki-67 expression declines with age, and its upregulation in research models has been associated with increased endothelial proliferative activity and vascular repair markers.

3. What effects has Vesugen been associated with in animal models of vascular aging?

In aged hypertensive rats, treatment with vascular peptide bioregulator increased microvasculature density in the pial membrane by 2.5 to 2.8-fold and was associated with approximately 1.7-fold increases in cerebral cortical blood oxygen saturation compared to untreated controls (5). These findings are consistent with increased angiogenic activity and measurable shifts in tissue perfusion parameters, aligning with the proposed mechanism of endothelial cell proliferation modulation through Ki-67 upregulation.

4. How does Vesugen relate to Cardiogen in cardiovascular aging research?

Vesugen (vascular) and Cardiogen (cardiac) represent complementary bioregulators within the Khavinson framework, each targeting a distinct tissue type within the cardiovascular system. Vesugen modulates endothelial cell proliferation, vascular signaling, and adhesion pathways, while Cardiogen targets cardiomyocyte gene expression, p53-mediated apoptosis, and contractile protein synthesis. Both compounds downregulate p53 in their respective tissues, suggesting a shared senescence-modulating mechanism operating through tissue-specific chromatin interactions.

5. What are the main limitations of the current Vesugen evidence base?

The primary limitations include the concentration of published research within a single institutional network (the Saint Petersburg Institute), the computational nature of the MKI67 molecular docking findings (which predict but do not confirm in vivo binding), limited sample sizes in animal studies, and incomplete pharmacokinetic characterization. While the mechanistic specificity of Vesugen research is notable compared to many other bioregulator compounds, independent international replication using contemporary blinded protocols and experimental binding validation techniques would substantially strengthen the evidence base.

References

1. Khavinson, V. Kh. (2009). Peptide bioregulation of aging: results and prospects. Biogerontology, 10(4), 401.
2. Khavinson, V. Kh., & Popovich, I. G. (2021). Peptide regulation of gene expression: A systematic review. Molecules, 26(22), 7053.
3. Khavinson, V. Kh., Tarnovskaya, S. I., Linkova, N. S., Gutop, E. O., & Elashkina, E. V. (2015). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology, 5(3), 150–155.
4. Khavinson, V., Linkova, N., Dyatlova, A., et al. (2023). Senescence-associated secretory phenotype of cardiovascular system cells and inflammaging: perspectives of peptide regulation. Cells, 12(1), 106.
5. Khavinson, V. Kh., et al. (2017). Effects of vascular peptide bioregulator on cerebral microcirculation of old hypertensive rats. Advances in Gerontology, 30(4), 540–545.
6. Khavinson, V. Kh., et al. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Cells, 11(7), 1087.
7. Khavinson, V. Kh. (2013). Peptide bioregulators: the new class of geroprotectors. Communication 1: Results of experimental studies. Advances in Gerontology, 3(3), 225–235.
8. Khavinson, V. Kh. (2013). Peptide bioregulators: the new class of geroprotectors. Communication 2: Clinical studies results. Advances in Gerontology, 3(3), 236–245.